HLN

Haleon plc

NYSE: HLN · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$8.98

+1.79% today

Updated 2026-06-05

Market cap

$40.34B

P/E ratio

18.24

P/S ratio

3.66x

EPS (TTM)

$0.50

Dividend yield

2.12%

52W range

$9 – $11

Volume

8.2M

Market cap

$40.34B

P/E ratio

18.24

P/S ratio

3.66x

EPS (TTM)

$0.50

Dividend yield

2.12%

52W range

$9 – $11

Volume

8.2M

Haleon plc (HLN) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

HLN · Haleon plc · Price target summary

Current

$8.98

Consensus

$11,470,000,000.00

+127728284977.95%

2030 Target

$35.77

+298.33%

DCF

—

Current price

$8.98

Analyst consensus

$11,470,000,000.00

+127728284977.95%

2030 Target

$35.77

+298.33%

Intrinsic (DCF)

—

21 analysts:

1 Buy2 Hold0 Sell

Management guidance

No specific CEO revenue targets found in available data. Company reported 3% organic growth in 2025 (down from prior guidance). Management has not published explicit revenue targets for 2026-2030 period.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

HLN · Haleon plc · Revenue & price projection · 2023–2030E

Actual revenue Projected revenue Base case Bull to bear range

Bear case (2030)

$23.84

$13.4B Rev × 8x P/S

Base case (2030)

$35.77

$13.4B Rev × 12x P/S

Bull case (2030)

$60.60

$13.4B Rev × 20x P/S

WallStSmart.com

Financial forecast — research-backed

Metric	2025	2026 (E)	2027 (E)	2028 (E)	2029 (E)	2030 (E)
Revenue	$10.8B	$11.8B	$12.3B	$12.7B	$13.1B	$13.4B
Revenue growth	-4.0%	6.8%	4.4%	3.3%	2.8%	2.7%
EPS	$0.34	$0.21	$0.23	$0.25	$0.26	$0.27
P/S ratio	—	12.0x	12.0x	12.0x	12.0x	12.0x
Implied price	—	$31.79	$32.79	$33.78	$34.77	$35.77

HLN · Haleon plc · Catalysts & risks

Growth catalysts

+ US shelf reset in retail channels expected to drive H2 2026+ growth

+ China emerging market expansion strategy and consumer health focus

+ Oral health innovation center (£130m investment) launching new products

+ Portfolio of 21 powerbrands (Sensodyne, Panadol, Voltaren, Centrum) with pricing power

+ Weak flu season headwinds easing with easier 2026-2027 comps

Key risks

- 2025 revenue guidance miss: achieved only 3% organic growth vs. company target, indicating execution challenges

- Weak consumer spending in North America impacting OTC product demand

- Mild winter conditions reduced respiratory/cold product sales

- Analyst sentiment deteriorating: 2 downgrades in 2025, multiple PT cuts

- Haleon's mid-term targets now viewed as 'not credible' by some analysts per Feb 2026 reports

- Share dilution from ongoing buyback program (8.9M shares canceled in March 2026)

Methodology

Haleon plc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 21 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.